Products & Services · Net Sales
Surgical — Net Sales
Edwards Lifesciences Surgical — Net Sales increased by 10.1% to $276.20M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase suggests strong demand for traditional surgical heart valve replacement and repair procedures, while a decrease may indicate a shift in clinical preference toward less invasive transcatheter alternatives.
Detailed definition
This metric represents the total revenue generated from the sale of surgical structural heart products, including tissue...
Peer comparison
Comparable to the surgical or open-heart product revenue segments of other medical device manufacturers specializing in cardiovascular health.
Metric ID:
ew_segment_surgical_net_salesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $250.90M | $276.20M |
| QoQ Change | — | +10.1% |
| YoY Change | — | +10.1% |
Range$250.90M – $276.20M
Avg YoY Growth+10.1%
Median YoY Growth+10.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's surgical — net sales?
- Edwards Lifesciences (EW) reported surgical — net sales of $276.20M in Q1 2026.
- What does surgical — net sales mean?
- Total revenue generated from the sale of surgical heart valve and repair products.